A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma

Trial Profile

A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Plerixafor (Primary) ; Filgrastim
  • Indications Non-Hodgkin's lymphoma; Stem cell mobilisation
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top